PEPITEM 'Replacement Therapy' Shows Promise for Early-Stage Inflammatory Arthritis

Researchers have demonstrated that PEPITEM, a naturally occurring immunopeptide, can reduce joint swelling in early inflammatory arthritis to levels comparable with current standard treatments. The therapy also appears to minimize the inflammatory changes responsible for progressive joint damage, offering potential benefits for patients seeking to prevent long-term disability. These findings represent an important advance in understanding how the body's own immune molecules might be harnessed therapeutically. If further clinical trials prove successful, PEPITEM replacement therapy could become a valuable new treatment option for patients with early-stage inflammatory arthritis, potentially slowing disease progression and preserving joint function.